Charles River Laboratories International Inc. and CHDI Foundation, Inc. have announced an extension of their ongoing drug discovery partnership aimed at advancing therapeutic development for Huntington's disease. This extension marks the 20-year anniversary of their collaboration, which began in 2005. The renewed agreement will enhance flexibility and integration across Charles River's global scientific network, supporting CHDI's programs. The partnership has contributed to significant advancements, including novel drug targets, translational research models, and preclinical evaluations of therapeutic candidates. The collaboration has also resulted in 15 composition of matter patent applications, reflecting its impact on Huntington's disease research and potential treatment options.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.